Clinical Laserthermia Systems

Kristian Waldeck holds a PhD in Experimental Clinical Pharmacology from Lund University and a MSc in Electrical Engineering with a Biomedical Focus from Chalmers University of Technology. After his medical postgraduate education, Kristian has worked for over 25 years in senior positions in life science and medical devices, where the common denominator has been clinical implementation of technologies that has enabled the establishment of new value-creating treatment options or care processes. Kristian's previous work experience includes Arjo, Hemocue, Mitra Medial, Prostalund and his own consulting company.             

"In line with the company's plan, we are working to build a solid foundation of clinical data for our products in selected indication areas and in selected geographic markets. The aim of this work is to ensure that CLS meets current regulatory requirements in the markets in which we are active and supports sales of our products in the EU, North America, and Asia Pacific. I am therefore very pleased to welcome Kristian to CLS. Kristian will be able to contribute with valuable knowledge and leadership to enable us to achieve the important milestones that lie ahead. He also complements our already strong team," says Dan Mogren, CEO of CLS.

Kristian Waldeck replaces Hoda Tawfik in the CLS management team. However, Hoda Tawfik will continue to contribute to CLS's continued development, but as a consultant in her own company, and will then be engaged in selected projects.

The information was submitted for publication, through the agency of the contact person set out below on 19 December 2023, at 12:00 CET.

Contact Information:

Dan J. Mogren, CEO, Clinical Laserthermia Systems AB (publ)

Phone: +46 705 90 11 40

E-mail: dan.mogren@clinicallaser.com

About CLS

Clinical Laserthermia Systems AB (publ) develops and sells the TRANBERG®|Thermal Therapy Systems, including Thermoguide Workstation and sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy, according to regulatory approvals in the EU and the US. The products are marketed for image-guided laser ablation and used in studies for treatment with imILT®, the Company's interstitial laser thermotherapy for immunostimulant ablation with potential abscopal effects. CLS is headquartered in Lund and has subsidiaries in Germany, the US and Singapore. CLS is listed on the Nasdaq First North Growth Market under the symbol CLS B. The Certified Advisor (CA) is FNCA Sweden AB

For more information about CLS, please visit the Company's website: www.clinicallaser.se